Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | 2025-10-28 16:45:39 | 35.7 | 0.93 | 2.67 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE | 0001515673 | Ultragenyx Pharmaceutical Inc. | US90400D1081 | 529900EV44GVDN1DCX77 | 272546083 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 60 LEVERONI COURT | NOVATO | CA | 94949 | UNITED STATES | US | 415-483-8800 | 60 LEVERONI COURT, NOVATO, CA, 94949 | 60 LEVERONI COURT, NOVATO, CA, 94949 | — | Biotechnology | 2010 | — | 893 | http://ultragenyx.com | 3,700,000,000 | 72,174,307 | 96,371,643 | Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. | 2025-10-23 13:39:12 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 3,700,000,000 | 600,000,000 | 19.3548 | 92,501,126 | 10,165,439 | 12.3463 |
| 2023 | 3,100,000,000 | -200,000,000 | -6.0606 | 82,335,687 | 12,118,998 | 17.2594 |
| 2022 | 3,300,000,000 | -3,200,000,000 | -49.2308 | 70,216,689 | 831,915 | 1.199 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Erik Harris | Chief Commercial Officer, Executive Vice President | 2024 | 604,231 | 0 | 2,271,944 | 367,235 | 13,800 | 4,295,813 |
| Eric Crombez | Chief Medical Officer, Executive Vice President | 2024 | 591,846 | 0 | 2,271,944 | 382,030 | 13,800 | 4,298,223 |
| Emil D. Kakkis | Chief Executive Officer, President | 2024 | 856,008 | 0 | 9,374,511 | 757,768 | 13,800 | 13,717,687 |
| Howard Horn | Chief Financial Officer, Executive Vice President | 2024 | 590,000 | 0 | 2,271,944 | 343,970 | 13,800 | 4,296,049 |
| John R. Pinion | Executive Vice President | 2024 | 570,366 | 0 | 2,084,548 | 339,768 | 13,800 | 4,129,753 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 1,294 |
| 2023 | 1,276 |
| 2022 | 1,311 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 560,230,000 | 434,249,000 | 363,329,000 |
| Cost Of Revenue | 76,728,000 | 45,209,000 | 28,320,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 697,865,000 | 648,449,000 | 705,789,000 |
| General And Administrative Expenses | 321,610,000 | 309,799,000 | 278,139,000 |
| Operating Expenses | — | — | — |
| Operating Income | -535,973,000 | -569,208,000 | -648,919,000 |
| Net Income | -569,183,000 | -606,639,000 | -707,421,000 |
| Earnings Per Share Basic | -6.29 | -8.25 | -10.12 |
| Earnings Per Share Diluted | -6.29 | -8.25 | -10.12 |
| Weighted Average Shares Outstanding Basic | 90,538,118 | 73,543,862 | 69,914,225 |
| Weighted Average Shares Outstanding Diluted | 90,538,118 | 73,543,862 | 69,914,225 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 173,729,000 | 213,584,000 | 132,944,000 |
| Marketable Securities Current | 436,296,000 | 363,625,000 | 614,818,000 |
| Accounts Receivable | 121,801,000 | 73,390,000 | 40,445,000 |
| Inventories | 45,007,000 | 33,969,000 | 26,766,000 |
| Non Trade Receivables | 1,800,000 | 1,100,000 | 6,400,000 |
| Other Assets Current | — | 47,616,000 | — |
| Total Assets Current | 817,123,000 | 732,184,000 | 883,899,000 |
| Marketable Securities Non Current | 135,004,000 | 199,901,000 | 148,970,000 |
| Property Plant And Equipment | 265,929,000 | 290,566,000 | 259,726,000 |
| Other Assets Non Current | 62,680,000 | 57,685,000 | 16,846,000 |
| Total Assets Non Current | 686,333,000 | 758,829,000 | 661,545,000 |
| Total Assets | 1,503,456,000 | 1,491,013,000 | 1,545,444,000 |
| Accounts Payable | 38,756,000 | 42,114,000 | 43,274,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 4,280,000 | 196,486,000 | 204,678,000 |
| Total Liabilities Current | 344,153,000 | 280,437,000 | 261,210,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 17,082,000 | 12,205,000 | 4,820,000 |
| Total Liabilities Non Current | 897,006,000 | 935,162,000 | 931,740,000 |
| Total Liabilities | 1,241,159,000 | 1,215,599,000 | 1,192,950,000 |
| Common Stock | 92,000 | 82,000 | 70,000 |
| Retained Earnings | -3,956,844,000 | -3,387,661,000 | -2,781,022,000 |
| Accumulated Other Comprehensive Income | -643,000 | 647,000 | -6,573,000 |
| Total Shareholders Equity | 255,297,000 | 275,414,000 | 352,494,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 35,543,000 | 26,006,000 | 18,220,000 |
| Share Based Compensation Expense | — | — | — |
| Other Non Cash Income Expense | 3,489,000 | -2,300,000 | 230,000 |
| Change In Accounts Receivable | 33,598,000 | 22,778,000 | 12,068,000 |
| Change In Inventories | 11,207,000 | 6,930,000 | 9,701,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | -15,325,000 | — |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -414,188,000 | -474,806,000 | -380,465,000 |
| Purchases Of Marketable Securities | 408,613,000 | 526,382,000 | 614,735,000 |
| Sales Of Marketable Securities | 3,247,000 | 50,672,000 | 84,275,000 |
| Acquisition Of Property Plant And Equipment | 7,491,000 | 44,267,000 | 116,123,000 |
| Acquisition Of Business | 0 | 0 | 75,025,000 |
| Other Investing Activities | 2,436,000 | 5,048,000 | 844,000 |
| Cash From Investing Activities | -17,768,000 | 168,000,000 | -291,652,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 0 | -28,000 | -555,000 |
| Cash From Financing Activities | 399,241,000 | 388,142,000 | 501,208,000 |
| Change In Cash | -35,240,000 | 81,798,000 | -171,984,000 |
| Cash At End Of Period | 173,729,000 | 213,584,000 | 132,944,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -6.29 | -8.25 | -10.12 |
| Price To Earnings Ratio | -6.6884 | -5.7964 | -4.5781 |
| Earnings Growth Rate | -23.7576 | -18.4783 | — |
| Price Earnings To Growth Ratio | 0.2815 | 0.3137 | — |
| Book Value Per Share | 2.8971 | 3.7449 | 5.0418 |
| Price To Book Ratio | 14.5215 | 12.7694 | 9.1892 |
| Ebitda | -533,640,000 | -580,633,000 | -689,201,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 10,906,000 | 56,846,000 | 136,699,000 |
| Free Cash Flow | -425,094,000 | -531,652,000 | -517,164,000 |
| Return On Equity | -2.2295 | -2.2026 | -2.0069 |
| One Year Beta | 0.9586 | 1.2199 | 1.1461 |
| Three Year Beta | 1.1246 | 1.1498 | 1.1247 |
| Five Year Beta | 1.1185 | 1.1859 | 1.262 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Horn Howard | Chief Financial Officer | 2025-10-13 | 7,942 | D | 98,227 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 2025-09-18 | 64 | D | 50,242 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 2025-09-12 | 2,450 | D | 73,271 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 2025-09-05 | 84 | D | 50,306 |
| Sanders Corazon (Corsee) D. | Director | 2025-06-20 | 2,405 | D | 15,344 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2025-09-12 | CA31 | Purchase | 2025-08-08 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-08-14 | CA31 | Purchase | 2025-07-15 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Campbell & CO Investment Adviser LLC | 2025-09-30 | 1,861,200 | 61,875 | 30.08 |
| Wilmington Savings Fund Society, FSB | 2025-09-30 | 812 | 27 | 30.0741 |
| Versant Capital Management, Inc | 2025-09-30 | 12,964 | 431 | 30.0789 |
| TD PRIVATE CLIENT WEALTH LLC | 2025-09-30 | 902 | 30 | 30.0667 |
| Quent Capital, LLC | 2025-09-30 | 6,497 | 216 | 30.0787 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| MFS SERIES TRUST I | 2025-08-31 | R1 | MNDGX | 388,060 | 11,626,277.6 | 0.558 |
| MFS SERIES TRUST I | 2025-08-31 | I | MNDIX | 388,060 | 11,626,277.6 | 0.558 |
| MFS SERIES TRUST I | 2025-08-31 | C | MNDCX | 388,060 | 11,626,277.6 | 0.558 |
| MFS SERIES TRUST I | 2025-08-31 | B | MNDBX | 388,060 | 11,626,277.6 | 0.558 |
| MFS SERIES TRUST I | 2025-08-31 | R4 | MNDJX | 388,060 | 11,626,277.6 | 0.558 |